Abstract:Objective The management of children with non-severe aplastic anemia (NSAA) is undefined and the efficacies and benefits of immunosuppressive therapy remain inconsistent. The study aimed to investigate the efficacy of Cyclosporine (CsA) monotherapy for pediatric NSAA. Methods Clinical data of children with NSAA who had been treated with CsA monotherapy at the outpatient department of Beijing Children's Hospital, Capital Medical University, National Children's Medical Center from January 2017 to March 2021 was collected retrospectively. Patients who had been treated <1 years until the end of follow-up were excluded. Transfusion-independent NSAA was further divided into moderate NSAA and mild NSAA according to the degree of cytopenia. Progression was defined as the development of transfusion-dependent AA or SAA and relapse was considered when treatment failed after initial response. Results A total of 95 pediatric patients with NSAA were enrolled in this study with 49 (51.6%) patients confirmed as mild NSAA, 38 (40%) as moderate NSAA and 8 (8.4%) as transfusion-dependent NSAA. The median treatment time of CsA was 22 (12–44) months. The overall response rate (ORR) was 57.9%, with 30.5% CR and 27.4% PR. Unexpectedly, patients with mild NSAA acquired lowest ORR (46.9%), then patients with moderate NSAA (63.2%), while 8 patients who were transfusion-dependent all had an active response to CsA. The granulocyte and megakaryocyte response was 46.9 and 55.8% respectively, while the erythrocyte response rate was as low as 22.5%. Univariate analyses revealed that patients with lower platelet count and higher interleukin 10 level predict an active response to CsA while higher level of fetal hemoglobin (HbF) tended to be a negative factor. Data of Treg cells before and after 1 year's treatment was available in a total number of 40 patients. Paired comparison found that the percentage of Treg cells in CD4+ T cells was decreased after 1 year's treatment of CsA (6.78 ± 2.72 vs. 5.23 ± 2.06, P = 0.001),both in responders and non-responders. The degree of decline in Treg cells between two distinctive response groups had no significant difference ( P >0.05). With a median follow-up time of 22 months, 10.9% of responders relapsed and maintained NSAA while 27.5% of non-responders progressed to SAA or became transfusion-dependent. The overall progression rate was 11.6%. Conclusion CsA monotherapy had heterogeneous effects in the treatment of children NSAA Treatment approaches should be hierarchical and individual in clinical. Patients with lower platelet count and higher interleukin 10 level predicted an active response to CsA. While higher level of fetal hemoglobin (HbF) tended to be a negative factor. The percentage of Treg cells in CD4+ T cells was decreased broadly after treatment.

Cyclosporine A blood concentration monitoring and its impact on the efficacy of 70 children with aplastic anemia in Peking University People's Hospital

Blood Concentration Monitoring of Cyclosporine A in Patients with Aplastic Anemia

Effect of Cyclosporin A in the Treatment of Aplastic Anemia in Children

Age Difference of Cyclosporin Dosage in Pediatric Patients

Analysis of the Outcome and Prognostic Factors of Cyclosporine A in Children with Non-severe Aplastic Anemia

Cyclosporine Monotherapy in Pediatric Patients With Non-severe Aplastic Anemia: A Retrospective Analysis

Investigation of Monitoring Whole Blood Concentration of Cyclosporine A in the Patients after Allogeneic Hematopoietic Stem Cell Transplantation

Cyclosporine blood concentration in 553 cases allogeneic hematopoietic stem cell transplant recipients

Effectiveness of Immunosuppressive Therapy for Childhood Aplastic Anemia and Its Predictive Factors

Treatment Outcome of 301 Aplastic Anemia Patients in China: a 10-Year Follow-Up and Real-World Data from Single Institute Experience

Clinical analysis of immunosuppressive therapy in childhood aplastic anemia

Blood concentration and therapeutic efficacy of cyclosporine A in treatment of immuno-related pancytopenia:a correlation study.

Influential factors of response to childhood aplastic anemia treated with antithymocyte globulin and Cyclosporin A

Efficacy of cyclosporine A on treatment of 126 children with non-severe aplastic anemia

Evaluation of Factors Related to Blood Concentration of Cyclosporine A in Adult Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Preliminary investigation of monitoring whole blood concentration of cyclosporine A in the patients after allogeneic renal transplantation

The efficacy and safety of cyclosporine A plus androgen versus androgen alone for adult patients with non-severe aplastic anemia in China: a meta-analysis of randomized controlled trials

Cyclosporin A in Combination with Androgens for Treating 56 Patients with Aplastic Anemia

Therapeutic effects of a combination of high-dose immunoglobulin and cyclosporine A in children with aplastic anemia

EFFECTS OF N ' Z CYCLOSPORINE COMBINED WITH ANDROGEN ON SERUM TH1/TH2 CELLS AND RELATED CYTOKINES AND T CELL SUBSETS IN PATIENTS WITH CHRONIC APLASTIC ANEMIA

Cyclosporine A and Tacrolimus Combined with Enteric-Coated Mycophenolate Sodium Influence the Plasma Mycophenolic Acid Concentration - a Randomised Controlled Trial in Chinese Live Related Donor Kidney Transplant Recipients